Skip to main content
. 2016 Sep 18;2016(9):CD006992. doi: 10.1002/14651858.CD006992.pub2

Kaku 2014.

Methods Randomised, double‐blind, 12‐week comparative trial, followed by a 40‐week, open‐label phase
Participants 179 participants with type 2 diabetes
Interventions Alogliptin and insulin versus placebo and insulin
Outcomes HbA1c, body weight, hypoglycaemia
Notes